Line 176: | Line 176: | ||
$('#postthree').animate({'opacity':'0'}, 0); | $('#postthree').animate({'opacity':'0'}, 0); | ||
$('#postfour').animate({'opacity':'0'}, 0); | $('#postfour').animate({'opacity':'0'}, 0); | ||
− | $('#spacer').animate({'height':' | + | $('#spacer').animate({'height':'110vh'}, 0); |
n=2; | n=2; | ||
}); | }); | ||
Line 188: | Line 188: | ||
$('#postthree').animate({'opacity':'0'}, 0); | $('#postthree').animate({'opacity':'0'}, 0); | ||
$('#postfour').animate({'opacity':'0'}, 0); | $('#postfour').animate({'opacity':'0'}, 0); | ||
− | $('#spacer').animate({'height':' | + | $('#spacer').animate({'height':'110vh'}, 0); |
n=3; | n=3; | ||
}); | }); | ||
Line 200: | Line 200: | ||
$('#posttwo').animate({'opacity':'0'}, 0); | $('#posttwo').animate({'opacity':'0'}, 0); | ||
$('#postfour').animate({'opacity':'0'}, 0); | $('#postfour').animate({'opacity':'0'}, 0); | ||
− | $('#spacer').animate({'height':' | + | $('#spacer').animate({'height':'110vh'}, 0); |
n=4; | n=4; | ||
}); | }); |
Revision as of 23:54, 18 October 2016
![](https://static.igem.org/mediawiki/2016/a/ad/T--BostonU--Intro.png)
![](https://static.igem.org/mediawiki/2016/6/6c/T--BostonU--DefinitionBubble.png)
![](https://static.igem.org/mediawiki/2016/7/7e/T--BostonU--SoftwareBub.png)
![](https://static.igem.org/mediawiki/2016/e/ed/T--BostonU--HisPartOne.png)
![](https://static.igem.org/mediawiki/2016/7/7d/T--BostonU--HisPartTwo.png)
During our first few weeks of iGEM, we attended a conference on mammalian synthetic biology. Part of this conference included a panel discussion of intellectual copyright and patent law. However, most of the conference goers did not attend this segment. We spoke with several professors in synthetic biology at Boston University. You can hear their interviews below. A link to full pdf transcripts of the interviews can be found at the bottom of this page.
Based on these discussions, we learned that this lack of participation stemmed from either a lack of interest or lack of understanding of intellectual property rights. However, this subject area is vital to synthetic biology, and intellectual property rights can have serious consequences. Therefore, we took it upon ourselves to create a blog called "Who Owns What" to help educate the synthetic biology community in this area. Hover over the buttons below to see a description of each post, and click on the button to load a pdf of each post. Our full blog with each post can be found on wordpress: here
Our post, “A General Overview of Intellectual Property in Synthetic Biology: Part 1” began our blog series by going over the basics of intellectual property. In essence, the post provided needed background and definitions such as patent, copyright and trademark, as well as a roadmap to future posts. Click the button above to load a pdf version of this post.
Our post, “A General Overview of Intellectual Property in Synthetic Biology: Part 2” continued the flurry of necessary definitions from Part 1, but went farther and began drawing comparisons between intellectual property in synthetic biology and the closest cousin in regards to policy and property laws: software. Click the button above to load a pdf version of this post.
Our post, “IP in Synthetic Biology: Part 1” offers a brief history of intellectual property from the beginning of such laws in Venice in the late 1400s to the beginning of the copyright and patent system in the U.S. in the 1790s. The post poses questions to the reader to induce a discussion in how intellectual property laws have expanded in breadth of protection since the beginning. Click the button above to load a pdf version of this post.
Coming Soon!